A-319

N/A

Report date: 2026/03/19 16:46:16

Base Information

Drug NameA-319
Drug Alias Name重组抗CD19m-CD3抗体A-319
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisArthritis, Rheumatoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEvive Biotech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesITabMed Co LtdEvive (Shanghai) Corp Ltd
Inactive CompaniesEvive Biotech Ltd
Active IndicationsLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisArthritis, Rheumatoid +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A